Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6301 to 6315 of 8940 results

  1. 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no treatment?

    Recommendation ID CG152/3 Question 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's

    Research recommendation
    Published
    17 September 2020

  2. Further research should be in the form of randomised controlled trials or registries. It should report:

    Recommendation ID IPG778 Question Further research should be in the form of randomised controlled trials or registries. It should report:

    Research recommendation
    Published
    11 January 2024

  3. What interventions are effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK?

    Recommendation ID NG146/2 Question What interventions are effective and cost effective in supporting return to work after recurrent short-term

    Research recommendation
    Published
    10 February 2020

  4. For people with common mental health conditions, what interventions are effective and cost effective in reducing long-term sickness absence and supporting return to work in the UK?

    Recommendation ID NG146/3 Question For people with common mental health conditions, what interventions are effective and cost effective

    Research recommendation
    Published
    10 February 2020

  5. What interventions are effective and cost effective in supporting return to work, in all workplaces including micro-, small- and medium-sized organisations, after long-term sickness absence in the UK?

    Recommendation ID NG146/1 Question What interventions are effective and cost effective in supporting return to work, in all workplaces

    Research recommendation
    Published
    10 February 2020

  6. Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation over the long term, what is the clinical and cost effectiveness of single-use non-coated versus single-use hydrophilic versus single-use gel reservoir versus reusable non-coated catheters with regard to the following outcomes: symptomatic urinary tract infections, urinary tract infection-associated bacteraemia, mortality, patient comfort and preference, quality of life, and clinical symptoms of urethral damage?

    Recommendation ID CG139/3 Question Intermittent urinary catheters: catheter selection:- For patients performing intermittent self-catheterisation

    Research recommendation
    Published
    9 June 2015

  7. Management of smouldering myeloma:- Which combinations of FISH, molecular technologies, bone marrow plasma cell percentage, whole-body imaging, immunophenotype, serum-free light-chain levels or ratio, Hevylite, paraprotein levels, immunoparesis, and International Staging System (ISS) are most effective at risk stratification for people with smouldering myeloma? What is the comparative effectiveness of fixed duration treatment (with or without bone-directed therapy), continuous treatment (with or without bone-directed therapy) and no treatment (with or without bone-directed therapy) for people with smouldering myeloma?

    Recommendation ID NG35/3 Question Management of smouldering myeloma:- Which combinations of FISH, molecular technologies, bone marrow plasma

    Research recommendation
    Published
    5 April 2016

  8. Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

    Recommendation ID NG35/4 Question Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem

    Research recommendation
    Published
    5 April 2016

  9. Imaging investigations for newly diagnosed myeloma:- What is the comparative effectiveness of whole-body MRI, fluorodeoxyglucose positron emission tomography CT (FDG PET-CT) and whole-body low-dose CT in detecting lesions that may determine the start of treatment for people with newly diagnosed myeloma?

    Recommendation ID NG35/2 Question Imaging investigations for newly diagnosed myeloma:- What is the comparative effectiveness of whole-body

    Research recommendation
    Published
    5 April 2016

  10. Diagnostic investigations to predict treatment outcomes:- What is the prognostic value of the Hevylite assay and ratio compared with other prognostic factors and tests, including the serum-free light-chain assay and fluorescence in-situ hybridisation (FISH), in people with newly diagnosed myeloma who are starting treatment?

    Recommendation ID NG35/1 Question Diagnostic investigations to predict treatment outcomes:- What is the prognostic value of the Hevylite

    Research recommendation
    Published
    5 April 2016

  11. Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic acid given indefinitely compared with zoledronic acid given for a fixed duration in patients with myeloma?

    Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic

    Research recommendation
    Published
    5 April 2016

  12. Simple home test prevents thousands of unnecessary bowel cancer referrals

    A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.

    News
    Last updated
    6 February 2026

  13. Faster, fairer access to HealthTech under new national programme

    People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).

    News
    Last updated
    9 February 2026

  14. Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives

    Home News Podcasts Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives Podcasts 17 December 2025 Listen

    News
    Last updated
    30 January 2026

  15. Getting medicines to NHS patients faster with aligned decisions with the MHRA

    Home News Podcasts Getting medicines to NHS patients faster with aligned decisions with the MHRA Podcasts 12 November 2025 Listen About this

    News
    Last updated
    30 January 2026